Ads
related to: medication for bronchitis in adults dosage
Search results
Results From The WOW.Com Content Network
[5] [10] Treatment of acute bronchitis typically involves rest, paracetamol (acetaminophen), and NSAIDs to help with the fever. [3] [6] Cough medicine has little support for its use and is not recommended in children less than six years of age. [1] [11] Antibiotics should generally not be used. [12] An exception is when acute bronchitis is due ...
While acute bronchitis often does not require antibiotic therapy, antibiotics can be given to patients with acute exacerbations of chronic bronchitis. [21] The indications for treatment are increased dyspnoea, and an increase in the volume or purulence of the sputum. [ 22 ]
Acute bronchitis is one of the more common diseases. [7] [14] About 5% of adults and 6% of children have at least one episode a year. [2] [15] Acute bronchitis is the most common type of bronchitis. [16] By contrast in the United States, in 2018, 9.3 million people were diagnosed with the less common chronic bronchitis. [17] [18]
Benzonatate is a prescription non-opioid alternative for the symptomatic relief of cough.[7] [9] It has been found to improve cough associated with a variety of respiratory conditions including asthma, bronchitis, pneumonia, tuberculosis, pneumothorax, opioid-resistant cough in lung cancer, and emphysema.
It is a combination drug containing three active ingredients - theophylline, ephedrine, phenobarbital. [2] This medication relaxes the smooth muscle of the airways, making breathing easier. [ 3 ] The common side effects of Tedral include gastrointestinal disturbances , dizziness , headache and lightheadedness .
Dosage typically includes information on the number of doses, intervals between administrations, and the overall treatment period. [3] For example, a dosage might be described as "200 mg twice daily for two weeks," where 200 mg represents the individual dose, twice daily indicates the frequency, and two weeks specifies the duration of treatment.
A further randomised, double blind, placebo-controlled clinical study with 413 patients confirmed the good efficacy and tolerability of ELOM-080 in the treatment of acute bronchitis. Half of the patients suffered from severe or very severe coughing and 86% exhibited pathological findings by auscultation.
In 2013, the drug was approved for use in the United States by the Food and Drug Administration (FDA) for long-term maintenance treatment of airflow obstruction in people with COPD, including chronic bronchitis and emphysema, [6] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma. [7]